Cochrane · systematic review · CD001289
Mucolytics for bronchiectasis
Wilkinson, M, Sugumar, K, Milan, SJ, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
9
No studies
12
Included studies
NR
No studies 12 · 57.1%Ungraded 0 · 0%Very low 0 · 0%Low 9 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bromhexine compared with placebo for bronchiectasis
Population: patients with bronchiectasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency and duration of exacerbations Bromhexine vs placebo | no estimate extracted | NR | No studies |
Hospitalisations Bromhexine vs placebo | no estimate extracted | NR | No studies |
Adverse events Bromhexine vs placebo | OR 2.93 [0.12, 73.97] | 1 study · 88 participants | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life Bromhexine vs placebo | no estimate extracted | NR | No studies |
Symptoms difficulty in expectoration Bromhexine vs placebo | no estimate extracted | 1 study · 88 participants | Low Downgraded: risk of bias, imprecision |
Deaths Bromhexine vs placebo | no estimate extracted | NR | No studies |
Lung function FEV1 Bromhexine vs placebo | MD 184 | 1 study · 88 participants | Low Downgraded: risk of bias, imprecision |
RhDNase compared with placebo for bronchiectasis
Population: patients with bronchiectasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency and duration of exacerbations RhDNase vs placebo | no estimate extracted | NR | No studies |
Hospitalisations for infective exacerbations RhDNase vs placebo | OR 5.54 [0.25, 123.08] | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Adverse events RhDNase vs placebo | no estimate extracted | NR | No studies |
Health‐related quality of life RhDNase vs placebo | no estimate extracted | NR | No studies |
Symptoms sputum colour Scale used not reported RhDNase vs placebo | MD 0.28 | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Deaths RhDNase vs placebo | OR 3.09 [0.32, 29.98] | 1 study · 349 participants | Low Downgraded: risk of bias, imprecision |
Lung function % change FEV1 RhDNase vs placebo | MD 2.1 | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Erdosteine versus no treatment for bronchiectasis
Population: patients with bronchiectasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency and duration of exacerbations Erdosteine vs no treatment | no estimate extracted | NR | No studies |
Hospitalisations for infective exacerbations Erdosteine vs no treatment | no estimate extracted | NR | No studies |
Adverse events Erdosteine vs no treatment | no estimate extracted | NR | No studies |
Health‐related quality of life Erdosteine vs no treatment | no estimate extracted | NR | No studies |
Symptoms mucus volume production Erdosteine vs no treatment | MD 0.4 | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |
Deaths Erdosteine vs no treatment | no estimate extracted | NR | No studies |
Lung function change in FEV1 (L) at day 15 Erdosteine vs no treatment | MD 200 [40, 360] | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |